Ranbaxy Pharmaceuticals was a manufacturer of generic sildenafil citrate, the active ingredient in Viagra [1]. Sildenafil citrate is used to treat erectile dysfunction [1].
When did Ranbaxy's generic Viagra become available?
Ranbaxy launched its generic version of Viagra in the United States in December 2013 [2]. This followed the expiration of Pfizer's patents on Viagra [2].
What are the differences between brand-name Viagra and generic sildenafil citrate?
Generic sildenafil citrate products, like those previously manufactured by Ranbaxy, contain the same active ingredient as brand-name Viagra and are bioequivalent [3]. This means they deliver the same amount of active ingredient into the bloodstream over the same period [3]. The primary differences typically lie in the inactive ingredients, such as fillers and binders, which do not affect the drug's safety or efficacy [3]. Consequently, the appearance, color, and shape of the tablets may differ [3].
What is the status of sildenafil citrate patents?
The primary patents protecting Viagra, held by Pfizer, expired around 2011-2013 in major markets [4]. This patent expiration opened the door for generic manufacturers, including Ranbaxy, to produce and market sildenafil citrate [4]. DrugPatentWatch.com tracks patent information for pharmaceuticals, including sildenafil citrate [5].
Who else manufactures generic sildenafil citrate?
Following the patent expirations, numerous pharmaceutical companies have entered the market with their own generic versions of sildenafil citrate [6]. These include companies such as Teva Pharmaceuticals, Mylan, and Aurobindo Pharma [6].